CTLA4 and diffuse large B-cell lymphoma: ,20 The use of immune-checkpoint inhibitory antibodies targeting these receptors or their ligands has recently revolutionized the treatment of several tumor entities,21,22 but only a modest antitumor activity was observed in patients suffering from DLBCL on PD-1 and CTLA-4 blockade therapy.23